Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

BMC Cancer
Aleksandar SekulicERIVANCE BCC Investigators

Abstract

In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration-approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally advanced BCC (laBCC), respectively. ORRs by investigator review were 45% (mBCC) and 60% (laBCC). Herein, we present long-term safety and final investigator-assessed efficacy results in patients with mBCC or laBCC. One hundred four patients with measurable advanced BCC received oral vismodegib 150 mg once daily until disease progression or intolerable toxicity. The primary end point was IRF-assessed ORR. Secondary end points included ORR, duration of response (DOR), progression-free survival, overall survival (OS), and safety. At data cutoff (39 months after completion of accrual), 8 patients were receiving the study drug (69 patients in survival follow-up). Investigator-assessed ORR was 48.5% in the mBCC group (all partial responses) and 60.3% in the laBCC group (20 patients had complete response and 18 patients had partial response). ORRs were comparable across patient subgroups, including aggressive histologic subtypes (eg, infiltrative BCC). M...Continue Reading

References

May 1, 1991·Journal of the American Academy of Dermatology·J S LoG J Hruza
Jun 1, 1984·Journal of the American Academy of Dermatology·H von Domarus, P J Stevens
Jan 15, 1994·Cancer·S N SnowJ Feyzi
Jun 28, 2005·Cancer Letters·Leela Daya-Grosjean, Sophie Couvé-Privat
Dec 15, 2010·Journal of Skin Cancer·Erika VargaLajos Kemény
Feb 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LoRussoDaniel D Von Hoff
Jun 8, 2012·The New England Journal of Medicine·Aleksandar SekulicAxel Hauschild
Jun 8, 2012·The New England Journal of Medicine·John T Lear
Mar 16, 2013·Current Opinion in Oncology·Aleksandar SekulicPatricia M LoRusso
Jul 6, 2013·American Journal of Epidemiology·Shaowei WuAbrar A Qureshi
Jan 15, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Margaret McCuskerAxel Hauschild
May 20, 2015·Journal of the American Academy of Dermatology·Aleksandar SekulicUNKNOWN ERIVANCE BCC investigators

❮ Previous
Next ❯

Citations

Dec 2, 2017·International Journal of Molecular Sciences·Marta Prieto-VilaTakahiro Ochiya
Mar 21, 2018·American Journal of Therapeutics·Bilal KhalidMohammad Razaq
Apr 27, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Miroslava DidiasovaMalgorzata Wygrecka
Jul 26, 2018·The New England Journal of Medicine·Kishwer S Nehal, Christopher K Bichakjian
Jun 3, 2017·Molecular Carcinogenesis·Anshika BakshiMohammad Athar
Aug 28, 2018·Plastic and Reconstructive Surgery·Bernardino M Mendez, James F Thornton
Dec 7, 2018·The Cochrane Database of Systematic Reviews·Naomi ChuchuUNKNOWN Cochrane Skin Cancer Diagnostic Test Accuracy Group
Feb 14, 2018·BMJ Case Reports·Prabhjot S BediHeather Laird-Fick
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Richard L Carpenter, Haimanti Ray
Feb 15, 2019·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Berenice M LangStephan Grabbe
Feb 15, 2019·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Berenice M LangStephan Grabbe
Jan 16, 2019·Endocrine-related Cancer·G CarrenoJ P Martinez-Barbera
Jan 30, 2019·The British Journal of Dermatology·B Y YanA M Rossi
Feb 9, 2019·Journal of Interpersonal Violence·Sarah M PeitzmeierSari L Reisner
May 28, 2019·Dermatologic Therapy·Massimiliano ScalvenziMilena Cappello
Aug 23, 2019·The American Journal of Dermatopathology·B BancalariO Sanmartín
Oct 1, 2019·Clinical & Experimental Ophthalmology·Gayatri CaplashDinesh Selva
Nov 21, 2019·The Australasian Journal of Dermatology·Matthew Gibson, Dedee Frances Murrell
May 1, 2019·Cells·Hao XieMartin E Fernandez-Zapico
Sep 27, 2019·Cancers·Malgorzata BobrowiczMagdalena Winiarska
Jan 26, 2020·International Journal of Molecular Sciences·Barbara BelleiLaura Eibenschutz
Jan 3, 2020·Advances in Anatomic Pathology·Michele BiscegliaDavid J Ben-Dor
Feb 9, 2020·International Journal of Dermatology·Romina CozzaniUNKNOWN ML29740 Investigators
Jan 29, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·R DummerR J J Grob
Mar 25, 2020·American Society of Clinical Oncology Educational Book·Evan T HallShailender Bhatia
Mar 25, 2020·International Ophthalmology Clinics·Davin C Ashraf, M Reza Vagefi
May 13, 2020·Oncology Reviews·Alena FurdovaJuraj Sekac
Jul 6, 2019·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Ethan Routt, Desiree Ratner
Jul 28, 2020·Dermatologic Therapy·Cosimo Di RaimondoGiulia Spallone
May 16, 2018·Rare Tumors·Mariana Orduz RobledoArjen F Nikkels
Jul 22, 2018·Drugs·James E Frampton, Nicole Basset-Séguin
Jun 28, 2019·Targeted Oncology·Ralf Gutzmer, James A Solomon
Aug 23, 2019·Acta chirurgica Belgica·Jos VellemanJan J Vranckx
Sep 25, 2019·Annals of Surgical Oncology·Ann Y Lee, Russell S Berman
Sep 23, 2020·Cancers·Debolina GangulyMatteo Ligorio
Oct 5, 2017·Dermatologic Therapy·Efthymia SouraAlexander Stratigos

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation
biopsy

Clinical Trials Mentioned

NCT00833417

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.